Please Wait...

Classic Blog

Risk-Based Monitoring Technology: 5 Essential Capabilities

  • 0
  • 27 Jan

If you've spent time researching risk-based monitoring (RBM) over the past year, you know dozens of academics, CROs, clinical trial practitioners, and statisticians have proposed varied approaches based on sponsor needs and trial designs. Unfortunately, despite an abundance of theoretical perspectives on RBM, clinical trial teams soon discover a significant gap still exists between perspectives and actual tools to enable real-world RBM implementation.

Read More

Time to Take Action and Make Risk-Based Monitoring a Reality

  • 0
  • 19 Jan

Intense interest surrounding RBM shows alignment of all the right elements — technology, regulatory bodies and the industry itself – to make risk-based monitoring a reality. If implemented with the right components, this approach could result in the most efficient trial management possible.

Read More

What’s New with CDISC Standards?

  • 0
  • 16 Dec

Progress on CDISC Standards has come at a quickened pace in recent years. Helping make advancement of industry-wide standards possible is collaboration among CDISC and other participating organizations (Critical Path Institute, Association of Clinical Research Organizations, Innovative Medicines Initiative, and National Cancer Institute). Joining in the collaboration are regulatory authorities and the pharma industry itself, as well as TransCelerate Biopharma which continues to press forward with its standards initiative.

Read More

Evolution of the Clinical Data Management Role, 1994-2014

  • 0
  • 09 Dec

20-Year Retrospective

The role of the Clinical Data Manager (CDM) has changed immensely since 1994, both in terms of role and function. Let's take a fun retrospective look at the great strides made in our field over these last 20 years, and more importantly, where the CDM role is headed. Let's begin with 1994, in honor of the Society of Clinical Data Management (SCDM), which commemorated its 20th Anniversary in 2014.

Read More
3 Reasons to Share Data from Unsuccessful Clinical Trials

3 Reasons to Share Data from Unsuccessful Clinical Trials

  • 0
  • 25 Nov

A recent proposal by the U.S. Department of Health and Human Services (HHS) could expand the amount of clinical trial data that drug companies must share with the public. Under the proposal, clinical trial sponsors would be required to report findings for drugs and devices that fail to reach approval.
 

Read More

eSource: Are You On-Trend with Other Sponsors?

  • 0
  • 12 Nov

eSource is a topic that has everyone talking and it continues to dominate the conversation at industry gatherings, including the annual SCDM conference held earlier this fall. From what I heard there − and continue to hear – sponsors' experience with eSource runs the full gamut.

Read More

Risk-Based Monitoring Versus Intelligent Monitoring

  • 0
  • 31 Oct

When I speak on the topic of risk-based monitoring (RBM) at industry events, someone invariably comes up afterward to say how nice it is we finally stopped talking about risk-based monitoring!

Read More

eSource: Still in the Shallow End of the Pool?

  • 0
  • 23 Oct

Dipping a toe in the water is always easier than jumping right into something new.

I am reminded of this old axiom as I look back at the recent SCDM conference and see it holds true for eSource.

Testing different eSource modalities within a controlled environment is one way to get acclimated and explore the use of eSource in your clinical trials while building experience – all in a low-risk way. Beginning with data that's directly entered as eSource is a whole lot easier and safer than attempting to hit it 100 percent from the high dive on the first try.

Read More
7 Principles of eSource Use

7 Principles of eSource Use

  • 0
  • 17 Oct

As I write this, I’m on a return flight home to Philadelphia from Las Vegas where I attended the Annual SCDM conference. It was a great event and I’m pretty revved up to share what I saw and heard there, especially on the evolving topic of eSource.

One session I’d like to tell you about is an eSource roundtable that was moderated by Linda King, Director of Global Data Delivery at Eli Lilly and Demetris Zambas, VP and Global Head, Data Management at Novartis. Representatives from CDISC, Merck, J&J, AssisTek, Quintiles, and Otsuka rounded out the expert panel.

Read More

Response to TransCelerate’s Risk-Based Monitoring Paper: Technology Considerations to Enable Risk-Based Monitoring Methodology

  • 0
  • 30 Sep

Have you had a chance to read the latest TransCelerate paper on risk-based monitoring (RBM)?

If not, I highly recommend getting your eyes on Technology Considerations to Enable the Risk-Based Monitoring Methodology, published online in August on behalf of the Drug Information Association (DIA). This paper serves as a tremendous resource for any organization interested in new enterprise technology to help realize the advantages of risk-based monitoring.

Read More
Highlights from the 2014 Osteoarthritis Imaging Workshop

Highlights from the 2014 Osteoarthritis Imaging Workshop

  • 0
  • 23 Sep

This summer, experts from academia, industry and regulatory sectors gathered in Reykjavik, Iceland for The International Workshop on Osteoarthritis Imaging (IWOAI) to discuss the latest advances related to imaging in Osteoarthritis (OA). Presentations at this conference centered on new imaging techniques and analytical methods for monitoring OA pathophysiology and evaluating imaging data from clinical studies.

Read More

FDA Insights: A Video Series Featuring FDA Perspectives on Clinical Trials, Part 2

  • 0
  • 19 Sep
BioClinica's Jonathan Andrus sits down with FDA official Sean Kassim, Ph.D., to discuss FDA Audits, Cloud Computing, Mobile Technology, Risk-Based Monitoring, eSource, ePRO, and Other Compliance and Quality Topics in Clinical Trials. See the videos of their discussion here!
Read More

Pages

4 Considerations for Choosing Key Risk Indicators (KRIs)

  • 0
  • 14 Sep

As a project manager and subject matter expert for Bioclinica's Compass RBM software, I've seen more and more companies turning to intelligent monitoring tools to track site performance and put their risk-based monitoring strategy into practice. When setting up a tool such as Compass, it's essential to choose the most important aspects of your trial to track in order to monitor site performance and identify areas on which to focus the most attention.

Read More

6 Advantages of an Agile Approach to Interactive Response Technology (IRT)

  • 0
  • 13 Sep

In clinical trials, randomization and trial supply management (RTSM) solutions help randomize the participant allocation and ensure the study design is balanced and trial supplies are available when and where they are needed. A key piece of those efforts is the use of interactive response technology (IRT) software.

Read More

Post-Approval Research: Do You Have What It Takes?

  • 0
  • 08 Sep

Investments in post-approval research are rising steadily year on year. Chances are, post-approval research represents a substantial part of your annual budget. But how much of that money is being wasted by conducting post-approval studies in an inappropriate and inefficient manner?

Read More

For EDCs, Flexibility is Key

  • 0
  • 06 Sep

Given the number of data sources that have to be integrated with your electronic data capture system (EDC), it's important to take flexibility into consideration when choosing an EDC. However, some EDCs make integrating with other systems easier than others. Bioclinica's Express EDC was built by data managers for data managers, so we understand how important ease of integration is in an EDC, and we built it with that flexibility in mind.

Read More

Pages

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is divided into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging and Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Biomarker Laboratory. Our eHealth segment comprises an eClinical Solutions Division along with Safety and Regulatory Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @lauren_chazal: Talking about metrics at MAGI East! @bioclinica #magieast2017 #magi17 https://t.co/vfsvbqbMnF
bioclinica (10 hours ago)
We have an incredibly experienced and motivated team focused on accelerating our ability to do what’s... https://t.co/HjjLpn7aAN
bioclinica (12 hours ago)
Industry latest via CenterWatch News Online https://t.co/hgyMUAL1oZ
bioclinica (15 hours ago)
RT @lauren_chazal: Envisioning e-research in 2020 #magi2017 @bioclinica https://t.co/SOvp0Cttia
bioclinica (15 hours ago)
[blog] A primer on #Biomarkers in #ClinicalResearch https://t.co/3rmy3rnKFb
bioclinica (3 days ago)
RT @ACRPDC: Happy #clinicaltrialsday! Join the celebration by telling us what you are doing as a #clinicalresearch professional. https://t.…
bioclinica (3 days ago)

Latest Blogs: